Introduction
============

Distant metastasis from primary breast cancer often occurs in the bones, lungs and liver. There are a few reports of metastasis to the gastrointestinal trunk \[[@B1]\], but cases of esophageal metastasis are extremely rare \[[@B2],[@B3]\]. We present the case of a patient who developed recurrence as esophageal metastasis following treatment of bilateral breast cancer. Early-stage gastric cancer was also found coincidentally. To the best of our knowledge, there have been no previous reports of such a case. We present this case with a discussion of the diagnosis and treatment strategies.

Case presentation
=================

An 86-year-old Japanese female patient with a history of bilateral breast cancer was found to have a gastric mass on a medical examination. She was referred to our hospital for a workup and treatment. She had previously undergone surgery for right breast cancer at 72 years of age and subsequently underwent total mastectomy with level II axillary lymph node dissection. The pathological examination at that time revealed invasive ductal carcinoma with positive lymphovascular invasion (pT3N0M0 stage II). The tumor was positive for both estrogen receptor (ER) and progesterone receptor (PR), and did not overexpress human epidermal growth factor receptor 2 (HER2). A total of 50Gy of external beam irradiation therapy was administered to her residual mammary gland, followed by endocrine therapy with 20mg of daily tamoxifen administration for five years. She was found to have left breast cancer at the age of 79 years. A total mastectomy was performed with level II axillary lymph node dissection, and invasive ductal carcinoma with positive lymphovascular invasion (pT1N0M0 Stage I) was diagnosed. As before, the tumor was positive for ER and PR with no HER2 overexpression. She received extended adjuvant endocrine therapy of 1mg per day of anastrozole for five years.

On her current admission, our patient complained of dysphagia. Repeat gastrofiberscopy revealed a submucosal lesion in her middle esophagus located 27cm distal to her incisors (Figure [1](#F1){ref-type="fig"}a), as well as the known type I tumor (semipedunculated type) of her gastric cardia (Figure [2](#F2){ref-type="fig"}). Biochemistry and blood testing did not reveal any abnormal values. Her level of squamous cell carcinoma antigen was elevated (5.4ng/mL); however, the values of the other markers (carcinoembryonic antigen, carbohydrate antigen 15--3, National Cancer Center-ST 439, cytokeratin 19 fragment) were within the normal ranges. Mediastinal computed tomography showed a mass lesion in her middle esophagus that had grown extraluminally and infiltrated the tracheal bifurcation and her left primary bronchus (Figure [3](#F3){ref-type="fig"}). There was no hepatic or pulmonary metastasis. Fine-needle aspiration cytology and a boring biopsy of the esophageal lesion were performed under ultrasonic monitoring (Figure [1](#F1){ref-type="fig"}b), and a pathological diagnosis of poorly differentiated adenocarcinoma of the esophagus was obtained with positive ER staining on immunohistochemistry (Figure [4](#F4){ref-type="fig"}a). A biopsy of the cardiac lesion revealed moderately differentiated adenocarcinoma of the stomach (Figure [4](#F4){ref-type="fig"}b). Neither hormone receptors nor HER2 were expressed in the gastric lesion. The expression status of the hormone receptors indicated that the esophageal lesion reflected metastatic recurrence of her breast cancer with coincidental primary gastric cancer (cT1N0M0 stage IA).

![**Gastrofiberscopy and fine-needle aspiration cytology. (a)** Gastrofiberscopy revealed a submucosal lesion of the middle esophagus. **(b)** Fine-needle aspiration cytology and a boring biopsy of the esophageal lesion were obtained under ultrasonic monitoring.](1752-1947-8-58-1){#F1}

![Gastrofiberscopy revealed a type I tumor (semipedunculated type) of the gastric cardia (a, b).](1752-1947-8-58-2){#F2}

![Mediastinal computed tomography showed a mass lesion on the middle esophagus that had grown extraluminally and had infiltrated the tracheal bifurcation and the left primary bronchus (a, b).](1752-1947-8-58-3){#F3}

![**Histological findings of the biopsy. (a)** Poorly differentiated adenocarcinoma of the esophagus. **(b)** Adenocarcinoma of the stomach.](1752-1947-8-58-4){#F4}

Although our patient's dysphagia progressed, neither intensive chemotherapy nor highly invasive surgical therapy were considered to be indicated due to her general condition and age. The esophageal lesion was treated with 2Gy per day of external beam irradiation therapy for 30 days (for a total of 60Gy). It remarkably reduced in size after radiotherapy (Figure [5](#F5){ref-type="fig"}a), allowing oral inoculation. The cardiac tumor exhibited no remarkable changes (Figure [5](#F5){ref-type="fig"}b). Endoscopic submucosal dissection was considered for the gastric tumor. Unfortunately, endoscopic ultrasonography (EUS) demonstrated that the tumor had invaded her submucosal layer and it was judged to be inoperable due to the risk of bleeding and perforation. The administration of chemotherapy and endocrine therapy for her breast cancer was prioritized because the esophageal lesion of the breast cancer was much more advanced and critical for our patient's status than the gastric cancer. She received metronomic medication with daily oral administration of tegafur-uracil (400mg per kilogram body weight), cyclophosphamide (100mg/day) and medroxyprogesterone acetate (800mg/day) based on her age and therapeutic history, as well as the biological subtype of the tumor and presence of the non-treated gastric cancer. She has since maintained a good performance status on outpatient treatment with chemo-endocrine therapy, and no disease progression had been noted to date, six months after the radiation therapy.

![**Gastrofiberscopy after radiotherapy. (a)** The esophageal tumor was remarkably reduced in size. **(b)** The cardiac tumor showed no remarkable change.](1752-1947-8-58-5){#F5}

Discussion
==========

Gastrointestinal metastasis of breast cancer is rare, with an incidence of 4.3% to 14.4% \[[@B1]\]. Although gastric metastasis of breast cancer is sometimes reported \[[@B1]\], metastasis to the esophagus occurs extremely rarely. According to Borst and Ingold, who observed a total of 2,246 patients with breast cancer over 18 years, the incidence of esophageal metastasis was only 0.4% \[[@B4]\]. There are very few case reports of such metastasis \[[@B5]-[@B19]\] (Table [1](#T1){ref-type="table"}); based on a search of PubMed, only 20 cases have been reported. We found no reports describing a case of gastric metastasis of breast cancer accompanied by gastric cancer or occurring after treatment for bilateral breast cancer.

###### 

Reported cases of esophageal metastasis from breast cancer

  **Author**                      **Year**   **Age**   **Location**   **Latent interval (years)**   **Treatment**   **Survival**
  ------------------------------ ---------- --------- -------------- ----------------------------- --------------- ---------------
  Haim *et al.*\[[@B5]\]            1989       50           Mt                    12                   D/HT/RT       1 year/AOD
  Issacs *et al.*\[[@B6]\]          1989       60         Mt, Lt                   5                    D/HT             -/-
  Shimada *et al.*\[[@B7]\]         1989       55           Lt                     9                    HT/OP        5 years/AOD
  Herrera \[[@B8]\]                 1992       78          EGJ                    21                    HT/OP        Postop/DOD
  Labenz *et al.*\[[@B9]\]          1993       61           Mt                    \-                      S         0.4 years/AOD
  Hastier *et al.*\[[@B10]\]        1994       42           Lt                     9                                    -/DOD
  Varanasi *et al.*\[[@B11]\]       1995       63           Mt                     8                    D/OP             -/-
  64                                 Mt        22        D/OP/RT              Postop/DOD                           
  78                                 Mt         8          D/OP               Postop/DOD                           
  67                               Mt, Lt      22        D/HT/RT              4 years/DOD                          
  Mizobuchi *et al.*\[[@B12]\]      1997       56           Lt                     7                  CT/HT/OP       4 years/DOD
  Fujii *et al.*\[[@B13]\]          1997       68           Mt                    15                    HT/OP        1 year/AOD
  Wu *et al.*\[[@B14]\]             1998       83           Mt                    13                    D/HT             -/-
  Simchuk and Low \[[@B2]\]         2001       73           Lt                     9                      D          1 year/DOD
  41                                 Mt         4          CT/D              0.1 years/DOD                         
  77                                 Mt        3.5          D                1.5 years/AOD                         
  74                                 Mt        11          D/S               0.4 years/DOD                         
  Erman *et al.*\[[@B15]\]          2002       55           Mt                    11                  CT/HT/RT       3 years/AOD
  Sunada *et al.*\[[@B16]\]         2005       68           Mt                    24                    D/HT        0.7 years/AOD
  Koike *et al.*\[[@B17]\]          2005       72           Mt                    23                     OP          1 year/AOD
  52                                 Lt        10         D/HT/S                  -/-                              
  Anaya *et al.*\[[@B18]\]          2006       67          EGJ                    19                    HT/OP       0.5 years/AOD
  Wada *et al.*\[[@B19]\]           2009       70           Mt                    16                    HT/RT       2.5 years/AOD
  Present case                      2011       86           Mt                     7                    HT/RT       0.5 years/AOD

AOD, alive of disease; CT, chemotherapy; D, dilatation; DOD, dead of disease; EGJ, esophagogastric junction; HT, hormonal therapy; Lt, lower thoracic esophagus; Mt, middle thoracic esophagus; OP, operation; RT, radiation therapy; S, stenting.

Esophageal metastasis of breast cancer is usually detected at an average of approximately seven years (range 3.5 to 24 years) after breast resection \[[@B20]\]. Symptoms include dysphagia, hoarseness and weight loss; however, such symptoms are observed only in approximately 30% of patients \[[@B21]\]. Esophageal metastasis of breast cancer causes compression or stenosis of the esophagus due to metastasis within the esophageal wall or to the mediastinal lymph nodes near the esophagus. Therefore, the mucosal surface is usually not involved. These features were also found in our patient. Esophagography and endoscopy are the diagnostic tools. The findings of these tests are characterized by regular stenosis of the esophagus as well as a lack of abnormalities of the mucosal surface. Biopsies often do not reveal malignant findings. Therefore, submucosal boring biopsies and aspiration cytology are recommended for biopsy-based diagnosis. Our patient was given a diagnosis based on successful EUS-guided fine-needle aspiration cytology and a boring biopsy, an alternative method for obtaining submucosal tumor tissues. Most esophageal metastases originating from breast cancer exhibit submucosal lesions \[[@B5]-[@B19]\]. Therefore, patients presenting with dysphagia should not be assumed to have benign stricture involvement even if a mucosal biopsy does not demonstrate malignancy. As a result, the indications for EUS are useful in such situations, as observed in our case.

The prognosis of metastatic breast cancer to the esophagus is poor, and it is reasonable to regard the disease as a highly advanced breast cancer \[[@B2],[@B20]\]. Therefore, the therapeutic strategy should always be individually planned. According to a literature review, surgical therapy has been performed in nine patients, four of whom survived for more than one year \[[@B7],[@B8],[@B11]-[@B13],[@B17],[@B18]\]. This result justifies the use of surgical treatment when deemed possible. By contrast, three patients died postoperatively, suggesting the highly invasive nature of surgical therapy when adapted to esophageal lesions \[[@B22]\]. The remaining patients were treated with dilatation, stenting and/or radiation in 13, three and six cases, respectively \[[@B5]-[@B19]\]. Only short-term follow-up results are available for patients who underwent dilatation and stenting (9). Radiation was administered in six cases \[[@B5],[@B11],[@B15],[@B19]\], with a relatively good prognosis of more than one year reported for every patient. All five patients who survived for more than two years received hormone therapy in combination with local treatment with either surgery or radiation. These results indicate that patients exhibiting a response to hormonal therapy, as in our case, may be expected to demonstrate a more favorable prognosis than patients with hormone receptor-negatives tumors. According to our review, as many as 13 of 24 patients with metastatic breast cancer to the esophagus showed positive results for ER and/or PR \[[@B5]-[@B8],[@B11],[@B17]-[@B19]\]. Therefore, it is thought that active treatment should be provided based on the intrinsic subtype. It is important to administer appropriate multimodal therapy with topical treatment for esophageal lesions (for example, radiotherapy, esophageal bougienage and esophagectomy) \[[@B7],[@B20]\] and systemic treatment for distant metastasis (for example, chemotherapy and endocrine therapy).

The administration of individualized treatment according to the intrinsic subtype is recommended in patients with breast cancer. Endocrine therapy was selected in our case because our patient's breast cancer was classified as luminal A type (ER-positive, HER2-negative, Ki67 \<14%). Toremifene, an aromatase inhibitor, was chosen for endocrine therapy because tamoxifen had been used for five years for the right breast cancer that developed at 72 years of age, and anastrozole for the same duration for the left breast cancer, possibly the lesion responsible for the present metastasis, that developed at 79 years of age. The primary tumors of both her breasts and the metastatic lesion demonstrated the same biological nature (ER-positive and HER2-negative). However, untreated early gastric cancer was also coincidentally found in our patient. Therefore, combination therapy was administered with tegafur-uracil, cyclophosphamide and medroxyprogesterone acetate. This combination therapy is reported to be useful for elderly patients \[[@B23]\].

Conclusions
===========

Esophageal metastasis of breast cancer is extremely rare. An individualized treatment plan combining multimodal approaches should therefore be devised according to the patient's status.
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